A recent in vitro study on human NSCLC cells, A549 and SK‐MES‐1 cells showed that CHE inhibited cell proliferation when used in combination with erlotinib.26 The combination treatment of CHE and erlotinib effectively blocked the EGFR signalling pathway through reducing phosphorylation in downstream targets such as STAT3, ERK1/2 and p38 MAPK. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.